Montelukast, Sıçanlarda Doksorubisinin Toksik Etkilerini Hafifletiyor: Histopatolojik Değerlendirme

Öz

Amaç: Doksorubisin (DOX), antineoplastik etkisine rağmen karaciğerde belirgin oksidatif stres ve hücresel hasara yol açmaktadır. Çalışmada DOX’un karaciğer dokusunda oluşturduğu oksidatif hasarın biyokimyasal, histolojik ve moleküler düzeyde ortaya konulması ve Montelukast’ın (ML) bu hasar üzerindeki koruyucu etkilerinin değerlendirilmesi amaçlanmıştır. Material Metot: DOX uygulamasının karaciğer dokusunda oluşturduğu oksidatif stresin daha kapsamlı değerlendirilmesi amacıyla Süperoksit Dismutaz (SOD), Katalaz (CAT), Glutatyon Peroksidaz (GPx) aktiviteleri ile indirgenmiş glutatyon (GSH) düzeyleri ve malondialdehit (MDA) seviyeleri analiz edilmiştir (p<0.05). Bulgular: Histopatolojik olarak portal alanlarda konjesyon, hepatositlerde piknotik nükleus, hücresel dejenerasyon ve sinüzoidal genişleme tespit edilmiştir. DOX + ML grubunda oksidatif stres göstergeleri iyileşmiş, SOD, CAT, GPx ve GSH azalırken MDA seviyeleri artış göstermiştir, histolojik bulgular hafiflemiş ve apoptotik gen ekspresyonları (Bax, Bcl-2, Caspase-3) DOX grubuna kıyasla anlamlı düzeyde modüle edilmiştir. Sonuç: Bulgular, ML’nin DOX’a bağlı oksidatif karaciğer hasarına karşı belirgin hepatoprotektif etki sağladığını göstermektedir.

Anahtar Kelimeler

• Doksorubisin
• karaciğer
• montelukast
• apoptoz

Destekleyen Kurum

Yok

Etik Beyan

Bu çalışma Çanakkale Deneysel Hayvan Etiği Kurulu tarafından onaylanmıştır (07.05.2021, Karar No: 2021-760).

Teşekkür

Yok

Multi-Mechanistic Hepatoprotective Effects of Montelukast Against Doxorubicin-Induced Liver Injury in Rats

Öz

Aim: Despite its antineoplastic effect, doxorubicin (DOX) causes significant oxidative stress and cellular damage in the liver. This study aimed to demonstrate the oxidative damage induced by DOX in liver tissue at the biochemical, histological, and molecular levels and to evaluate the protective effects of Montelukast (ML) on this damage. Material Method: To further evaluate the oxidative stress induced by DOX in liver tissue, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) activities, reduced glutathione (GSH) levels, and malondialdehyde (MDA) levels were analyzed (p<0.05). Results: Histopathologically, portal congestion, pyknotic nuclei in hepatocytes, cellular degeneration, and sinusoidal dilation were observed. In the DOX + ML group, oxidative stress markers improved, SOD, CAT, GPx, and GSH decreased, while MDA levels increased, histological findings were attenuated, and apoptotic gene expression (Bax, Bcl-2, Caspase-3) was significantly modulated compared to the DOX group. Conclusion: The findings suggest that ML provides a significant hepatoprotective effect against DOX-induced oxidative liver damage.

Anahtar Kelimeler

• Doxorubicin
• liver
• montelukast
• apoptosis

Destekleyen Kurum

None

Etik Beyan

This study was approved by the Çanakkale Experimental Animal Ethics Committee (07.05.2021, Decision No: 2021-760).

Teşekkür

None

Kaynakça

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229.
2. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157-170.
3. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106-135.
4. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic oxidative stress in rats: the protective effect of vitamin E and catechin. Toxicology. 2005;209(1):39-45.
5. Bhutani V, Varzideh F, Wilson S, Kansakar U, Jankauskas SS, Santulli G. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. J Cardiovasc Dev Dis. 2025;12(6):207.
6. Yagmurca M, Bas O, Mollaoglu H, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res. 2007;38(4):380-385.
7. Song S, Chu L, Liang H, Chen J, Liang J, Huang Z, et al. Protective Effects of Dioscin Against Doxorubicin-Induced Hepatotoxicity Via Regulation of Sirt1/FOXO1/NF-κb Signal. Front Pharmacol. 2019;10:1030.
8. Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, et al. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659.

9. Sarman E, Koca HB. Effect of grape seed extract on doxorubicin-induced testicular and epididymal damage in rats. Hum Exp Toxicol. 2025;44:9603271251319787.
10. Bilgiç Mİ, Altun G, Çakıcı H, Gideroğlu K, Saka G. The protective effect of Montelukast against skeletal muscle ischemia reperfusion injury: An experimental rat model. Ulus Travma Acil Cerrahi Derg. 2018;24(3):185-190.
11. Bilge H, Yildizhan E. Protective effects of taxifolin against oxidative stress and apoptosis in liver ischemia-reperfusion injury: an experimental animal study. Ann Surg Treat Res. 2025;109(1):53-60.
12. Duran A, Otiük H, Terzi EH, Tosun M, Oziiü H, Ocak T, et al. Protective effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against intestinal ischemia-reperfusion injury in the rat. Acta Chir Belg. 2013;113(6):401-5.
13. Kuru S, Kismet K, Barlas AM, Tuncal S, Celepli P, Surer H, et al. The Effect of Montelukast on Liver Damage in an Experimental Obstructive Jaundice Model. Viszeralmedizin. 2015;31(2):131-138.
14. Sobczuk P, Czerwińska M, Kleibert M, Cudnoch-Jędrzejewska A. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27(1):295-319.
15. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213-1225.
16. Soltani Hekmat A, Chenari A, Alipanah H, Javanmardi K. Protective effect of alamandine on doxorubicin-induced nephrotoxicity in rats. BMC Pharmacol Toxicol. 2021;22(1):31.
17. Coskun AK, Yigiter M, Oral A, Odabasoglu F, Halici Z, Mentes O, et al. The effects of montelukast on antioxidant enzymes and proinflammatory cytokines on the heart, liver, lungs, and kidneys in a rat model of cecal ligation and puncture-induced sepsis. ScientificWorldJournal. 2011;11:1341-1356.
18. Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339.
19. Hafez HM, Hassanein H. Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-α/NF-κB pathways. Drug Chem Toxicol. 2022;45(2):548-559.
20. Zhang J, Cui L, Han X, Zhang Y, Zhang X, Chu X, et al. Protective effects of tannic acid on acute doxorubicin-induced cardiotoxicity: Involvement of suppression in oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2017;93:1253-1260.
21. Saad MA, Abdelsalam RM, Kenawy SA, Attia AS, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochem Res. 2015;40(1):139-150.
22. Khodir AE, Ghoneim HA, Rahim MA, Suddek GM, et al. Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats. Hum Exp Toxicol. 2016;35(4):388-397.
23. Saad MA, Abdel Salam RM, Kenawy SA, Attia AS, et al. Pinocembrin attenuates hippocampal inflammation, oxidative perturbations and apoptosis in a rat model of global cerebral ischemia reperfusion. Pharmacol Rep. 2015;67(1):115-122.
24. Wang Z, Wu X, Liu J, Wang Y, Zhang Y, Wu Y, et al. Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope. Front Pharmacol. 2023;14:1285647.